Correction to “Targeting LncRNA-Vof16: A Novel Therapeutic Strategy for Neuropathic Pain Relief”

IF 4.8 1区医学 Q1 NEUROSCIENCES

CNS Neuroscience & Therapeutics Pub Date : 2025-04-28 DOI:10.1111/cns.70418

引用次数: 0

Abstract

X. He, D. H. Mauki, X. Zhao, et al., “Targeting LncRNA-Vof16: A Novel Therapeutic Strategy for Neuropathic Pain Relief,” CNS Neuroscience & Therapeutics 31, no. 2 (2025): e70241.

The “Funding” and “Acknowledgments” sections have been updated to acknowledge the valuable contribution of the National Natural Science Foundation of China (Grant No. W2433199).

We apologize for this error.

查看原文本刊更多论文

对“靶向LncRNA-Vof16：神经性疼痛缓解的新治疗策略”的更正

何晓霞，赵晓霞，赵晓霞，等，“靶向LncRNA-Vof16：治疗神经性疼痛的新方法”，《神经科学》；《治疗学》第31期，第1期。2 (2025): e70241。“基金资助”和“致谢”部分已更新，以感谢中国国家自然科学基金（批准号：No. 5502）的宝贵贡献。W2433199)。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS Neuroscience & Therapeutics 医学-神经科学

CiteScore

7.30

自引率

12.70%

发文量

240

审稿时长

2 months

期刊介绍： CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.